Gastro Medical News about Carcinoma, Hepatocellular

Your Unread Messages

See All

Tracy Hampton, PhD

FDA Update

Anti-CD20 Antibody Granted Accelerated Approval for CLL

Roberta Buell, MBA
CMS Revises Consignment Closet Provisions

Dorothy J. Schirf, MD

Technology Advances

Radiosurgery Trial Sparks Optimism for Early Lung Cancer

Sara Hartley

Cancer Science

Using Embryonic Stem Cells to Test Breast Cancer Genes

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Use of Antiemetic Agents in Acute Gastroenteritis

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

MiR-122 affects the viability and apoptosis of hepatocellular carcinoma cells
Scandinavian Journal of Gastroenterology, 11/06/09

Wu X et al. – MiR–122 down–regulated the viability but up–regulated the apoptosis of hepatoma cell Huh–7. The absence of miR–122 expression in HepG2 cells was due to the loss of the miR–122 coding sequence in chromosome 18. These results imply that aberrant expression of miR–122 may contribute to hepatocarcinogenesis.

<< Previous
Audit of eosinophilic oesophagitis in children post-liver...

Next >>
Oral administration of mesalazine protects against mucosal injury...